Research programme: dual RON/c-Met inhibitors - AmgenAlternative Names: Compound I
Latest Information Update: 16 Mar 2010
At a glance
- Originator Amgen
- Class Small molecules
- Mechanism of Action Proto oncogene protein c met inhibitors; RON protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Nov 2007 Preclinical trials in Cancer in USA (unspecified route)